Genentech announces FDA approval for Gazyva for active lupus nephritis

Genentech, a member of Roche (RHHBY), announced that the FDA has approved Gazyva for the treatment of adult patients with active lupus nephritis who are receiving standard therapy, as well as a shorter 90-minute infusion time after the first infusion, for eligible patients. Following four initial doses in the first year, Gazyva can be administered twice yearly, offering an effective and potentially more convenient treatment option than traditional targeted therapies.